TB drug could reduce mortality for MDR-TB and XDR-TB cases

September 26, 2012

Results from an observational study evaluating a new anti-TB drug have found that the treatment can improve outcomes and reduce mortality among patients with both MDR-TB and XDR-TB.

The research, published online ahead of print today in the , suggests a called delamanid could have a public health benefit for MDR-TB and also for XDR-TB, as few effective options are currently available.

Over the past two decades, multidrug-resistant TB (MDR-TB) has emerged as a significant , with strains of TB growing increasingly resistant to first-line drugs. MDR-TB hampers progress towards the global elimination of TB and recently it has further evolved into an even more resistant form, called extensively drug-resistant tuberculosis (XDR-TB).

The WHO Global Plan to Stop TB 2011-2015 has called for urgent development of with novel mechanisms of action to treat all forms of TB, including MDR and XDR-TB.

A randomised control trial has previously evaluated the effectiveness of 2 months treatment with different doses of the drug. The new study followed the same and observed the outcomes of their treatment for a further 24 months.

421 patients took part in the observational study and researchers examined the effects of delamanid when taken in combination with a -recommended background . The researchers classified the patients into either a favourable outcomes group, where the patient was cured or completed the treatment, or an unfavourable outcome, where the patient had failed the treatment course, defaulted or died.

The results found that 74.5% of patients taking delamanid for more than 6 months had favourable outcomes. This compared to 55% of patients taking the drug for less than 2 months. Furthermore, only two patient deaths occurred in the long-term group, compared to 19 in the short-term treatment group.

In the subset of patients suffering with XDR-TB, 61.4% of patients in the long-term group experienced favourable outcomes, compared with 50% in the short-term group. Mortality was also reduced within this subset.

Lead author, Vija Skripconoka from the Riga East University Hospital, said: "The observational study has shown that when delamanid is taken for at least 6 months with a WHO-recommended background treatment regimen, it can improve outcomes for patients with MDR-TB and XDR-TB. This is extremely positive news given that similar studies of different treatments rarely report favourable outcomes above 70% or mortality rates below 15%. The 1% mortality rate measured in this study is very promising. A further randomised-control study is currently enrolling a large group of people to confirm delamanid's effectiveness and monitor side-effects."

Related Stories

Trial for new drug-resistant TB treatment to begin

March 19, 2012

A global health alliance Monday unveiled plans for the first clinical tests of a new treatment regimen for tuberculosis, including for patients with resistance to existing multidrug programs.

Recommended for you

Can social isolation fuel epidemics?

July 21, 2015

Conventional wisdom has it that the more people stay within their own social groups and avoid others, the less likely it is small disease outbreaks turn into full-blown epidemics. But the conventional wisdom is wrong, according ...

Lack of knowledge on animal disease leaves humans at risk

July 20, 2015

Researchers from the University of Sydney have painted the most detailed picture to date of major infectious diseases shared between wildlife and livestock, and found a huge gap in knowledge about diseases which could spread ...

IBD genetically similar in Europeans and non-Europeans

July 20, 2015

The first genetic study of inflammatory bowel disease (IBD) to include individuals from diverse populations has shown that the regions of the genome underlying the disease are consistent around the world. This study, conducted ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.